Boehringer In­gel­heim buys CD38 drug; Mer­ck bets on ma­chine learn­ing in an­ti­body de­sign

CD38 may be best known as a tar­get for can­cer ther­a­pies — no­tably J&J’s Darza­lex and Sanofi’s Sar­clisa. But Boehringer In­gel­heim be­lieves it has po­ten­tial in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER